Key facts
- This page summarizes Kamal Hamed's Form 4 filing for Spero Therapeutics, Inc. (SPRO).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 05 Feb 2024, 20:45.
Kamal Hamed - 01 Feb 2024 Form 4 Insider Report for Spero Therapeutics, Inc. (SPRO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- SPRO
- Reported as of
- 01 Feb 2024
- Net transaction value
- -$38,463
- SEC form
- 4
- Accepted by SEC
- 05 Feb 2024, 20:45:12 UTC
- Prior SEC filing
- 15 Sep 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Tamara Joseph. Attorney-in-Fact for Kamal Hamed
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Kamal Hamed filed Form 4 for Spero Therapeutics, Inc. (SPRO) on 05 Feb 2024.
Change
- Previous filing in this sequence was filed on 15 Sep 2023.
- Current net transaction value: -$38,463.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
SPRO
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +239,731
- Change %
- +42%
- Price
- $0.000000
- Shares after
- 816,192
- Date
- 01 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
SPRO
transaction
Common Stock
Sale
- Transaction value
- $38,463
- Shares
- -28,075
- Change %
- -3.4%
- Price
- $1.37
- Shares after
- 788,117
- Date
- 02 Feb 2024
- Ownership
- Direct
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date.
Footnote F2
The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023 pursuant to a "sell to cover" provision included in the RSU Agreement.
Footnote F3
Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.